Kyle B. Lupo
Immunology and Microbiology · Purdue University West Lafayette
Publications
23
Citations
806
Est. group size
~7
Recurring co-author estimate
Active years
10
Publishing since 2016
Kyle B. Lupo's research focuses on engineering immune cells, particularly natural killer (NK) cells and NK-like T cells, to improve cancer immunotherapy. His work spans genetic engineering of these cells to overcome tumor-driven immune suppression, metabolic reprogramming of immune cells within tumors, and applications in solid tumors like glioblastoma as well as blood cancers like acute myeloid leukemia. This research is relevant to students interested in cell-based cancer therapies, immune cell engineering, and tumor immunology.
Publication output has been relatively steady with some fluctuation over the past decade, rising from 0-3 papers annually in 2017-2019 to a peak of 5 in 2021, followed by continued moderate activity averaging about 2 papers per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- PD-L1 ligation on NK cells induces a metabolic shift from glycolysis to fatty acid oxidation, enhancing tumor infiltration and control
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Engineered NKG2C <sup>+</sup> NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Abstract 5233: Engineered NK-like NKG2C+ CD8 T cells mediate superior anti-tumor efficacy over conventional CD8 T cells and NK cells
Cancer Research · 2024
- 89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia
European Journal of Nuclear Medicine and Molecular Imaging · 2024
- Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions
Cytotherapy · 2021
- 130 Engineered natural killer cells reactively block TIGIT and CD73 in the GBM microenvironment
Regular and Young Investigator Award Abstracts · 2021
- Immunometabolic targeting of NK cells to solid tumors
Elsevier eBooks · 2021
- CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma
Journal of Hematology & Oncology · 2020
- 123 Natural killer cells engineered with an inducible, responsive genetic construct targeting TIGIT and CD73 to relieve immunosuppression within the GBM microenvironment
Regular and Young Investigator Award Abstracts · 2020
- Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Cancers · 2019
- Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
Journal for ImmunoTherapy of Cancer · 2018
- Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells
Frontiers in Immunology · 2018
- On the Effective Length of Fluttering Finite-Length Pipes
46th AIAA Fluid Dynamics Conference · 2016
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Regular and Young Investigator Award Abstracts×3
- Frontiers in Immunology×2
- Elsevier eBooks×2
- Cancers×1
- Sandro Matosevic
Immunology and Microbiology · Purdue University West Lafayette
- Jianhua Yu
Immunology and Microbiology · The Ohio State University
- Dean A. Lee
Immunology and Microbiology · The Ohio State University
- Jilu Zhang
Immunology and Microbiology · Indiana University
- Shambhavi Borde
Immunology and Microbiology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile